Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Dr. Karl Thomae Gmbh

Karl Thomae Gmbh

Michael Mark

Frank Himmelsbach

Roland Maier

Matthias Eckhardt

Elke Langkopf

Mohammad Tadayyon

Thomas Klein

Leo Thomas

Klaus Dugi

Rudolf Hurnaus

Ralf Lotz

Hans-Juergen Woerle

Ralf R H Lotz

Bernhard Eisele

Gerhard Hallermayer

Rolf Grempler

Ralph-Michael Budzinski

Peter Muller

Eberhard Woitun

Norbert Hauel

Armin Heckel

Thorsten Lehmann-Lintz

Peter Eickelmann

Iris Kauffmann-Hefner

Eva Ulrike Graefe-Mody

Andreas Daiber

Maximilian Von Eynatten

Peter Baruch Mueller

Leo John Seman

Gebhard Adelgoss

Gebhard Schilcher

Bernard Eisele

Heike Zimdahl-Gelling

Sanjaykumar Patel

Manfred Reiffen

Wolfgang Grell

Robert Sauter

Uli Christian Broedl

Berthold Hocher

Odd-Erik Johansen

Thomas Muenzel

Rudolph Hurnaus

Stefan Kauschke

Odd-Eric Johansen

Gerd Luippold

Thomas Unger

Yuliya Sharkovska

Josep-Maria Sendra

Josef M E Leiter

Michael Schupp

Ralf Richard Hermann Lotz

Ulrich Kintscher

Heiko Niessen

Ralf Richard Lotz

Axel Riedel

The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.

Use of a DPP-4 inhibitor in SIRS and/or sepsis

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Uses of DPP IV inhibitors

The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Vasoprotective and cardioprotective antidiabetic therapy

The invention relates to a pharmaceutical composition according to the claimcomprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.

Combination therapy

The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.

Method for modifying food intake and regulating food preference with a DPP-4 inhibitor

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

Growing community of inventors

Biberach an der Riss, Germany

Michael Mark